Beractant


Concise Prescribing Info
Dosage Details
Endotracheal
Neonatal respiratory distress syndrome
Child: Premature neonates ≥700 g: Initially, 100 mg phospholipids/kg (4 mL/kg) given as soon as possible, preferably w/in 15 min of birth (as prophylaxis); or as soon as diagnosis of RDS is made, preferably w/in 8 hr of birth (as treatment). May repeat no more frequently than 6 hrly w/in 1st 48 hr of life up to a Max of 4 doses if there is evidence of continuing distress.
Special Precautions
Childn.
Adverse Reactions
Significant: Transient bradycardia and oxygen desaturation, nosocomial sepsis, endotracheal tube obstruction.
Nervous: Seizures, intracranial haemorrhage.
CV: Hypotension, HTN, tachycardia, ventricular tachycardia, aortic thrombosis, cardiac failure, cardio-respiratory arrest, increased apical pulse, persistent foetal circulation, air embolism, total anomalous pulmonary venous return.
GI: Abdominal distention, haemorrhage, intestinal perforations, volvulus, bowel infarct, feeding intolerance, stress ulcer.
Resp: Pulmonary haemorrhage, apnoea, emphysema, hypo- and hypercapnia, subglottic stenosis, paralyzed diaphragm, resp failure.
Hepatic: Hepatic failure.
Genitourinary: Renal failure, haematuria.
Endocrine: Adrenal haemorrhage, hyperphosphataemia.
Haematologic: Coagulopathy, thrombocytopenia, disseminated intravascular coagulation.
Musculoskeletal: Inguinal hernia.
Others: Fever, deterioration.
MonitoringParameters
Monitor continuous ECG and arterial or transcutaneous measurement of systemic oxygen and CO2 during admin, and arterial blood gases.
Action
Description: Beractant, a modified pulmonary surfactant, is a bovine lung extract of phospholipids. It replaces deficient or ineffective endogenous lung surfactant in neonates w/ resp distress syndrome (RSD). An efficient surfactant lowers surface tension between air and alveolar surface, hence preventing the alveoli to collapse during expiration.
Onset: Improved oxygenation: W/in minutes.
Pharmacokinetics:
Distribution: Rapidly distributes to the alveolar surfaces.
Excretion:
Storage
Store between 2-8°C. Do not freeze. Protect from light.
References
Anon. Beractant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/05/2017.

Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/05/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Beractant. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/05/2017.

Survanta Suspension (AbbVie Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/05/2017.

Disclaimer: This information is independently developed by MIMS based on Beractant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Survanta
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in